What we do
We have developed anti-complement antibodies as a treatment for complement-mediated disorders. These humanized monoclonal antibodies selectively block the complement alternative pathway (CAP) and do not block the complement classical pathway (CCP) which is required to control infections. Our two lead candidate humanized monoclonal antibodies (Anti-C3b and Anti-Bb) are unique in their mechanism of action and uniquely block the CAP but not the CCP.learn more
Both antibodies inhibit C3b and C5b-9 formation in serum from PNH patients suggesting that our two lead candidates are suitable for treating PNH disease with superiority over Soliris. Anti-Bb and Anti-C3b antibodies bind their target proteins with picomolar affinity.
We have generated significant in vitro and ex vivo data on Anti-C3b and Anti-Bb humanized monoclonal antibodies demonstrating that these antibodies block the CAP by blocking the formation of C3b and C5b-9. Unlike Soliris, our antibodies do not block the CCP. We have created an exciting pipeline of therapeutic candidates especially for orphan diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH), C3-Glomerulopathy (C3G), and Neuromyelitis Optica (NMO). We believe that our portfolio of therapeutic antibodies has the potential for a better safety and an upgraded efficacy profile than currently marketed drugs including those that are under development.